Switching from protease inhibitors to efavirenz: Differences in efficacy and tolerance among risk groups: A case-control study from the Swiss HIV Cohort

AIDS

Volumn 16, Issue 3, 2002, Pages 381-385

  Hirschel, Bernard ^a   Flepp, Markus ^a   Bucher, Heiner C ^a   Zellweger, Claudine ^a   Telenti, Amalio ^a   Wagels, Thomas ^a   Bernasconi, Enos ^a   Ledergerber, Bruno ^a   Battegay, M ^a   Burgisser Ph ^a   Egger, M ^a   Erb, P ^a   Fierz, W ^a   Francioli, P ^a   Furrer, H J ^a   Gorgievski, M ^a   Gunthard H ^a   Grob, P ^a   Klimkait, Th ^a   Opravil, M ^a   Paccaud, F ^a   Pantaleo, G ^a   Perrin, L ^a   Piffaretti, J C ^a   Rickenbach, M ^a   Rudin, C ^a   Sudre, P ^a   Schiffer, V ^a   Schupbach, J ^a   Vernazza, P ^a   Weber, R ^a   more..

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

Cohort study; Efavirenz; HAART; HIV; HIV protease inhibitors; Matched case control study

Indexed keywords

EFAVIRENZ; INDINAVIR; NELFINAVIR; PROTEINASE INHIBITOR; RITONAVIR;

ARTICLE; CASE CONTROL STUDY; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DATA BASE; DRUG CHOICE; DRUG EFFICACY; DRUG TOLERABILITY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; PRIORITY JOURNAL; SIDE EFFECT; SWITZERLAND; TREATMENT OUTCOME; VIRUS LOAD;

ADULT; CASE-CONTROL STUDIES; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; DRUG TOLERANCE; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; MALE; OXAZINES; REVERSE TRANSCRIPTASE INHIBITORS; RNA, VIRAL; SUBSTANCE ABUSE, INTRAVENOUS; SWITZERLAND;

EID: 0037084002     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200202150-00009     Document Type: Article

References (9)

1. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: A prospective cohort study. Swiss HIV cohort study
2. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: A cohort study
3. Study. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults
4. Clinical epidemiology and research on HIV infection in Switzerland: The Swiss HIV cohort study 1988-2000
5. 1993 Revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults
6. Efavirenz
7. Efavirenz decreases methadone blood concentrations
8. A randomized trial of three maintenance regimens given after three months of induction therapy with zidovudine, lamivudine, and indinavir in previously untreated HIV-1-infected patients
9. Simplified maintenance therapy with abacavir + lamivudine + zidovudine in patients with HAART-induced long-term suppression of HIV-1 RNA